Spyre Therapeutics, Inc. SYRE Free cash flow margin
Discontinued — last reported Q4 '22
Free cash flow margin at other companies
Other financials
Where this comes from
Calculated from Spyre Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Spyre Therapeutics, Inc.’s 10-K, filed February 27, 2025, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s free cash flow margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s free cash flow margin?
- Spyre Therapeutics, Inc. (SYRE) reported free cash flow margin of -3,442.8% in Q4 2022.
- How has Spyre Therapeutics, Inc.'s free cash flow margin changed year-over-year?
- Spyre Therapeutics, Inc.'s free cash flow margin decreased by 1045.1% year-over-year, from -300.7% to -3,442.8%.
- What does free cash flow margin mean?
- How much real, spendable cash each sales dollar generates after reinvestment.
- How do you interpret free cash flow margin?
- A high and rising FCF margin is the hallmark of a cash-generative business. Persistent gaps between net margin and FCF margin warrant a look at working capital or capital intensity.
- How does free cash flow margin compare across companies?
- Strong cross-company quality signal; capital-light compounders post structurally higher FCF margins than asset-heavy peers.